Curosurf®

Product description: Curosurf® is a hospital-administered treatment for respiratory distress syndrome (RDS) in premature babies. RDS is caused by a lack of surfactant, a slippery substance that lines the alveoli (tiny air sacs) of the lungs, helping to keep them inflated during the process of inhalation and exhalation.

Since its introduction in 1992, Curosurf® has become a well-established therapy that has been used to treat approximately 800,000 premature babies. Curosurf® is in-licensed from
Chiesi Farmaceutici.

Medical need: Premature babies can be born with little or no surfactant, which makes breathing difficult or impossible. The resulting medical condition, known as respiratory distress syndrome (RDS), affects approximately 1% of newborns and is a leading cause of death in premature babies.

Not all products or indications are available in all countries. Regulatory requirements in various countries limit the product information that we can provide. Please consult your physician about any medical condition or prescription product.